pharma news today obesity drugs glp-1 Agonists Weight Loss Market Report, 2025-2030 The next phase of the

Neuropeptides like Cerebrolysin or Dihexa, which modulate BDNF and synaptic plasticity, overlap with serotonergic pathways that antidepressants target creating unpredictable receptor saturation dynamics in preclinical models

Until comprehensive carcinogenicity studies are completed, individuals with active cancer, cancer history, or high genetic cancer risk should avoid BPC-157

The Connection Between Vitamin B12 and Weight Loss Research suggests that low B12 levels may be linked to increased fat accumulation and metabolic challenges [1]

Dihexa is now scheduled for PCAC review before the end of February 2027, alongside four other peptides: LL-37, GHK-Cu, PEG-MGF, and Melanotan II

Challenges and opportunities in delivering oral peptides and proteins

McGraw-Hill / Lange McCulloch DK (2017): Metformin in the treatment of adults with type 2 diabetes mellitus